On 2026-10-01, BTIG upgraded UTHR to Buy from Neutral.
BTIG 于 2026-10-01 将 UTHR 评级上调至 买入（Buy），此前为 中性（Neutral）。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
UTHR regulatory decision: United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary FibrosisUnited Therapeutics Corporation（UTHR）披露重大监管决定
Material Company Event · September 2, 2026公司公告 · 2026/9/2
UTHR buyback activity: $1.50B repurchased in Q1 (6.35% of market cap)美国联合医疗公司（UTHR）Q1 回购 $1.50B，约占市值 6.35%
Buyback Activity · June 1, 2026Buyback Activity · 2026/6/1
Wells Fargo upgrades UTHR from Equal Weight to OverweightUTHR · 评级变动
Rating Change · May 8, 2026评级变动 · 2026/5/8
